Japan’s Eisai Gets U.S. FDA Approvals For Two Drugs
This article was originally published in PharmAsia News
Executive Summary
The U.S. FDA has approved Eisai's Aloxi (palonosetron hydrochloride) anti-nausea drug for use in preventing post-surgery vomiting, and its Vasolan (verapamil) for treating atrial fibrillation. The Aloxi approval is for a new indication for the drug, approved five years ago for treating nausea caused by chemotherapy. Eisai anticipates up to $600 million total sales for the drug beginning in 2011. The Vasolan approval also is an additional indication, the drug having been approved earlier for treating coronary heart disease. (Click here for more